肺癌的免疫靶向治疗-蔡兴东__培训课件.pptVIP

* * * Primary Maximum tolerated dose Highest dose within a cohort in which no more than 1/6 patients experience dose-limiting toxicities (DLTs) DLT evaluation period was from first dose until administration of: Third dose of MEDI4736 + tremelimumab (for the cohort receiving 3 mg/kg MEDI4736 q4w and 1 mg/kg tremelimumab q4w); or Second dose of MEDI4736 + tremelimumab (other cohorts receiving MEDI4736 q4w); or Third dose of MEDI4736 and second dose of tremelimumab (cohorts receiving MEDI4736 q2w) Safety and tolerability Adverse events (AEs) and serious AEs (SAEs) graded according to the